In this article, we will take a look at some of the best growth stocks to invest in for the next 5 years.
Before making any decision, whether big or small, we instinctively weigh its long-term impact, and this is particularly true in the case of stocks. We have all asked at some time: How much return can I expect in the years ahead?
As the legend of investment, Warren Buffett, says,
“Only buy something that you’d be perfectly happy to hold if the market shut down for 10 years.”
We often hear that we should invest in a stock and then forget about it. But the real condition lies in the growth prospects of the stock. By definition, a growth stock is a company’s share that is expected to outperform the general market. The common features of such a stock are above-average earnings growth, higher risk, higher reward, and reinvestment of dividends. Given this, we will take a look at some of the best growth stocks.
A close-up of an investor pointing to a chart featured on a projector, conveying a message of growth.
Our Methodology
We have compiled a list of 15 stocks using the Finviz stock screener, filtering for upside potential of at least 50% and revenue growth of at least 20% in the last five years. After selecting the stocks, we ranked them according to their upside potential, from highest to lowest.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
15. Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)
Upside potential as of June 24, 2025: 51.52%
Gautam Patel, the director of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX), sold 94,906 shares of Class A Common Stock, worth around $761,146, on June 16, 2025. The prices fluctuated between $8.00 and $8.05 per share, while the current trading price stands at $7.92.
As a result of the transaction, Patel’s stake now amounts to 1,609,144 shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX). The sale was executed automatically in accordance with a pre-determined trading plan adopted on August 15, 2024, and in compliance with Rule 10b5-1(c). In general, analysts remain optimistic regarding the stock, with price targets ranging between $11 and $12 per share.
Just recently, analysts at Goldman Sachs reviewed the generic drug industry and initiated coverage on Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) with a positive outlook. The reasons cited were many, from current portfolio changes favoring higher-value products to the company’s track record of business execution. With a 12-month price target of $12, the analyst supported the potential upside of over 50%.
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX), headquartered in Bridgewater, New Jersey, is a leading biopharmaceutical company that develops and markets generics, injectables, biosimilars, and specialty branded pharmaceutical products. Founded in 2002, the company operates through three main segments: Affordable Medicines, Specialty, and AvKARE. The giant is committed to advancing innovation in healthcare.
14. Assembly Biosciences, Inc. (NASDAQ:ASMB)
Upside potential as of June 24, 2025: 71.12%
In the wake of its recent Annual Meeting of Stockholders, Assembly Biosciences, Inc. (NASDAQ:ASMB) has unleashed a wave of major approvals and shifts. While accepting two amendments to the company’s Amended and Restated 2018 Stock Incentive Plan (the “2018 Plan”), the stockholders elected Jeanette M. Bjorkquist as the chief financial officer.
As mentioned earlier, the 2018 Plan has been amended in two distinct ways: Amendment 1 raises the number of common stock shares for issuance to 1,478,333 from 1,103,333, whereas Amendment 2 reserves an additional 225,000 shares for issuance contingent upon performance-based vesting to strengthen an extensive supplemental retention grant program.
During the meeting, all director nominees were appointed to serve until the 2026 annual meeting of stockholders, and in the management change, Jeanette M. Bjorkquist, the principal executive officer of Assembly Biosciences, Inc. (NASDAQ:ASMB), will also serve as the CFO. These adjustments are a testament to the company’s efforts to incentivize performance and retain talent, positioning ASMB to perform well in the times ahead.
Assembly Biosciences, Inc. (NASDAQ:ASMB) is a California-based biotechnology company that develops therapeutic products for treating viral diseases. Incorporated in 2005, the company collaborates with Gilead Sciences, Inc. for the research and development of virology therapies. The giant is dedicated to delivering high-quality treatments.
13. Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)
Upside potential as of June 24, 2025: 89.54%
The General Counsel of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), David O. Watson, sold 5,000 shares of common stock for $18.77, higher than the current trading price of $17.62. This transaction, worth $93,850, although it follows a challenging period, implies the current undervaluation of the stock.
This reduction of the stake means that Watson now owns 133,730 shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) directly and 80,136 shares indirectly through a custodial account for his minor children and the David O. Watson Irrevocable Trust of 2023. With that being said, the execution of the sale was under a pre-arranged 10b5-1 trading plan.
Some analysts believe that if you hold this stock, you need to have some patience. They argue that the significant FCF potential of SYFOVRE and EMPAVELI can’t be overlooked, with the market for SYFOVRE anticipated to exceed $1 billion in annual sales by 2028. EMPAVELI, on the other hand, is undergoing trials for additional indications and is expected to contribute to EBITDA positivity by 2026.
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is a Massachusetts-based commercial-stage biopharmaceutical company that discovers and commercializes novel therapeutic compounds for underserved diseases. Incorporated in 2009, the company has a license agreement with Swedish Orphan Biovitrum AB (publ) and Beam Therapeutics Inc.
12. Akebia Therapeutics, Inc. (NASDAQ:AKBA)
Upside potential as of June 24, 2025: 101.36%
Akebia Therapeutics, Inc. (NASDAQ:AKBA) announced the approval of an amendment to the 2023 Stock Incentive Plan to make room for future growth. According to the amendment, which was authorized during the company’s Annual Meeting of Stockholders on June 10, 2025, the shares to be issued will increase by 18,900,000.
During the meeting, the two Class II directors, John P. Butler and Myles Wolf, M.D., M.M.Sc., were also elected until the annual meeting of stockholders in 2028. While John P. Butler received 130,424,556 votes, the latter secured 119,938,011 votes. The leadership changes follow the impressive one-year return of over 300% delivered by Akebia Therapeutics, Inc. (NASDAQ:AKBA), reinforcing its strong position in the market.
In addition to the stock incentive amendment plan and executive appointments, stockholders extended advisory approval to compensate the company’s named executive officers. With 178,590,132 votes cast in favor, Ernst & Young LLP was also selected as the giant’s independent registered public accounting firm for the fiscal year ending December 31, 2025.
Akebia Therapeutics, Inc. (NASDAQ:AKBA) is a Massachusetts-headquartered biopharmaceutical company that develops and commercializes therapies for people living with kidney diseases. Founded in 2007, the company offers Vafseo (vadadustat) and Auryxia, alongside the ongoing development of AKB-9090 and AKB-10108. Through a collaboration with Mitsubishi Tanabe Pharma Corporation, the company is dedicated to improving the lives of many.
11. Butterfly Network, Inc. (NYSE:BFLY)
Upside potential as of June 24, 2025: 108.89%
Analysts at TD Cowen reaffirmed their Buy rating on Butterfly Network, Inc. (NYSE:BFLY), with an unchanged price target of $5.00, signaling an upside of around 150% from the current levels. This optimism stems from the European Commission’s launch of a review period regarding the company’s proposal to withdraw its EU market exemption. Currently, the exemption protects the continued use of lead piezoelectric crystals in portable ultrasound devices.
The initiation marks a crucial moment in the company’s efforts to remove the market exemption for lead piezoelectric crystals, which are considered important for several handheld ultrasound devices. Having said that, public feedback will be accepted through August 1, with an expected recommendation to the European Commission by the second quarter of the upcoming fiscal year.
From expanding the target market for the company’s technologies to accelerating growth in the existing challenging market, the significance of this development can’t be denied. While the final decision is anticipated in the years ahead, investors are closely monitoring the company’s position as the decision in favor of Butterfly Network, Inc. (NYSE:BFLY) would set the stage for future growth.
Butterfly Network, Inc. (NYSE:BFLY) is a Massachusetts-based company that develops and markets ultrasound imaging solutions globally. The core offerings of the company include Butterfly iQ+ and iQ3 ultrasound devices, Butterfly iQ+ Bladder, and Butterfly iQ+ Vet. Incorporated in 2011, the giant is working to democratize medical imaging by making it accessible to everyone.
10. BTCS Inc. (NASDAQ:BTCS)
Upside potential as of June 24, 2025: 120.26%
According to a press release issued on Friday, BTCS Inc. (NASDAQ:BTCS) has announced the acquisition of 1,000 ether (ETH) for around $2.5 million via borrowing on decentralized lending protocol AAVE. This would allow the blockchain technology company to support the expansion of its NodeOps business by utilizing the newly acquired ether.
This transaction, with an average price of $2,528 per ETH, means that BTCS Inc. (NASDAQ:BTCS) now owns 14,600 ETH, implying a surge of 61% from the existing 9,063 ETH held at the end of the first quarter of 2025. As the CEO of BTCS Inc., Charles Allen, stated,
“Our approach has always been slow, steady, and strategic.”
Through AAVE’s lending platform, the company protected shareholder interest, with the initial net cost of capital noted to be around 2.78% per year. Just recently, FTSE Russell posted its preliminary list of companies slated to join the Russell Microcap Index, with BTCS Inc. (NASDAQ:BTCS) included among the technology names.
BTCS Inc. (NASDAQ:BTCS) is a Maryland-based company that offers blockchain infrastructure services in the United States. From Builder+ and NodeOps to ChainQ, the company has a diversified product portfolio. Founded in 2015, the company is dedicated to securing next-generation proof-of-stake blockchains.
9. Axogen, Inc. (NASDAQ:AXGN)
Upside potential as of June 24, 2025: 144.38%
On June 11, 2025, Axogen, Inc. (NASDAQ:AXGN) presented at the Goldman Sachs 46th Annual Global Healthcare Conference, where a strategic vision was highlighted that is focused on solidifying the company’s leadership in nerve repair solutions. The management remains confident about the giant’s position in delivering strong growth while expanding the product portfolio.
The company is undergoing a wave of transformative operational changes by adding new clinical application areas. With that being said, Axogen, Inc. (NASDAQ:AXGN) is working towards improving professional education activities and entering new areas.
The future outlook of Axogen, Inc. (NASDAQ:AXGN) looks equally promising. The company aims to expand internationally by 2026, with sustained investments in Avance and complementary products, targeting regeneration and protection devices. It doesn’t stop there; recognizing significant under-penetration in its existing markets, the company is committed to accelerating growth by advancing its commercial footprint and development initiatives.
Axogen, Inc. (NASDAQ:AXGN) is a Florida-based company that develops and markets technologies for peripheral nerve regeneration and repair worldwide. The company’s core offerings include Avance Nerve Graft, AxoGuard Nerve Connector, AxoGuard Nerve Protector, AxoGuard Nerve Cap, and AxoGuard HA+ Nerve Protector. Founded in 2002, the company is focused on improving patients’ lives.
8. Aquestive Therapeutics, Inc. (NASDAQ:AQST)
Upside potential as of June 24, 2025: 161.07%
Analysts at H.C. Wainwright have reaffirmed their $10.00 price target on Aquestive Therapeutics, Inc. (NASDAQ:AQST) while maintaining a Buy rating. This positive outlook follows the approval of a New Drug Application for Anaphylm by the U.S. Food and Drug Administration.
Earlier last week, Anaphylm, a leading non-device-based epinephrine product candidate for immediate treatment of severe allergic reactions, was accepted for review. The FDA has set a Prescription Drug User Fee Act date for January 31, 2026. Wallet portability, rapid onset, and high patient preference are among the many benefits provided by the leading drug that is well-positioned to secure a market share of $2 billion.
According to the management, Anaphylm has shown clinical outcomes on par with autoinjectors like EpiPen and Auvi-Q. Its sublingual administration is what sets it apart from nasal spray-based epinephrine products.
Aquestive Therapeutics, Inc. (NASDAQ:AQST), headquartered in New Jersey, is a pharmaceutical company that develops and markets solutions to address unmet medical needs. Incorporated in 2004, the company uses innovative drug delivery technologies like PharmFilm and Adrenaverse.
7. Actinium Pharmaceuticals, Inc. (NYSE:ATNM)
Upside potential as of June 24, 2025: 195.02%
During the Society of Nuclear Medicine & Molecular Imaging annual meeting in New Orleans, Actinium Pharmaceuticals, Inc. (NYSE:ATNM) showcased promising preclinical results for its prostate cancer candidate, ATNM-400.
The data indicated that the leading drug demonstrated superior cancer cell killing in contrast to Xtandi (enzalutamide) and greater efficacy than not only Pluvicto (177Lu-PSMA-617) but also Ac-225-PSMA-617 in both laboratory and animal models. As the Actinium’s Chairman and CEO, Sandesh Seth, stated,
“ATNM-400 is the ideal cornerstone of our emerging solid tumor pipeline.”
We have seen how Xtandi, developed by Astellas and Pfizer, secured $5.9 billion in sales in 2024, with Novartis’s Pluvicto generating $1.4 billion in the same period. Since ATNM-400 is the potential monotherapy or is complementary to the existing prostate cancer treatments, we have good reason to believe that the drug will be a turnaround point for Actinium Pharmaceuticals, Inc. (NYSE:ATNM).
Actinium Pharmaceuticals, Inc. (NYSE:ATNM), based in New York, develops antibody radiation conjugates and other targeted radiotherapies to address the failures of the current oncology therapies. With two clinical-stage product candidates, Actimab-A and Iomab-ACT, the giant aims to build a hospital-focused radiotherapeutics company.
6. Aytu BioPharma, Inc. (NASDAQ:AYTU)
Upside potential as of June 24, 2025: 347.76%
On Monday, Aytu BioPharma, Inc. (NASDAQ:AYTU) disclosed that it has successfully extended its lending agreement with Eclipse Business Capital LLC (“Eclipse”), offering additional working capital flexibility to support the upcoming commercial rollout of EXXUA (gepirone) extended-release tablets.
According to the agreement, the principal balance on the term loan has been raised to $13.0 million from $11.1 million, providing enhanced liquidity. Additionally, term loan maturity has been extended by 12 months to June 2029.
Just recently, Aytu BioPharma, Inc. (NASDAQ:AYTU) unveiled an exclusive agreement to commercialize EXXUA, enabling the company to enter a market of over $22 billion in prescription MDD in the United States alone. Although more than 40 million antidepressants were prescribed in the USA in 2024, significant unmet needs still exist, mainly due to the intolerable side effects associated with existing treatments. As the clinical trials with around 5,000 patients suggest, EXXUA has exhibited better performance in depression symptoms.
Aytu BioPharma, Inc. (NASDAQ:AYTU) is a Colorado-based pharmaceutical company that focuses on novel therapeutics in the United States and internationally. The core products of the company include prescription products for people living with attention deficit hyperactivity disorder (ADHD) and pediatric prescription products. With an emphasis on patient access, the company adopts bold and innovative strategies.
5. XTI Aerospace, Inc. (NASDAQ:XTIA)
Upside potential as of June 24, 2025: 376.14%
XTI Aerospace, Inc. (NASDAQ:XTIA) has filed a public offering of up to 4,558,404 shares of common stock at a par value of $0.001 per share and is committed to acquiring up to 4,558,404 shares of common stock.
The estimated public offering price of each common stock share, together with one accompanying Common Warrant, is reported to be $3.51. Having said that, XTI Aerospace, Inc. (NASDAQ:XTIA) plans to offer the stock with one Common Warrant, with an exercise price that is 125% of the offering price of the shares sold.
The shares of the company’s common stock and Common Warrants are not only immediately separable but also issued independently, yet they must be purchased together as part of this offering.
XTI Aerospace, Inc. (NASDAQ:XTIA) is a Colorado-based aircraft development company with a presence across the United States, Germany, and the United Kingdom. The core offerings of the company include TriFan 600, real-time location systems (RTLS), indoor intelligence software, and hardware products. Incorporated in 1999, the giant is committed to revolutionizing regional air travel.
4. BioLineRx Ltd. (NASDAQ:BLRX)
Upside potential as of June 24, 2025: 483.56%
H.C. Wainwright reaffirmed its Buy rating on BioLineRx Ltd. (NASDAQ:BLRX) while maintaining a price target of $26.00. This confidence follows the company’s participation in ASCO 2025, where the management presented full data from the pilot phase of its CheMo4METPANC Phase 2 trial.
While exhibiting superior efficacy in contrast to historical controls, the outcomes showcased an overall response rate and a disease control rate of 64% and 91%, respectively. What’s even more exciting is that four out of eleven patients remained progression-free even after a year of treatment. While one patient showed a complete radiologic resolution of liver metastases and secured definitive radiation to the primary pancreatic tumor, the other one maintained a sustained partial response, and upon undergoing pancreaticoduodenectomy, a complete response was noted.
These results set the foundation for the company to transform the trial into a randomized Phase 2 study with 108 patients. All of these efforts are a testament to the company’s strong footing in the coming years. Having said that, FTSE Russell recently announced the addition of BioLineRx Ltd. (NASDAQ:BLRX) to the Russell Microcap Index.
BioLineRx Ltd. (NASDAQ:BLRX) is a commercial-stage biopharmaceutical company that develops and commercializes therapeutics targeting oncology and rare diseases. Incorporated in 2003, the company is focused on fulfilling unmet medical needs through its drug development efforts.
3. Avalo Therapeutics, Inc. (NASDAQ:AVTX)
Upside potential as of June 24, 2025: 511.98%
On Monday, the management of Avalo Therapeutics, Inc. (NASDAQ:AVTX) revealed its participation in the HCW Annual Inflammation & Immunology Virtual Conference, scheduled for June 30, 2025, and BTIG Virtual Biotechnology Conference 2025, planned for July 29–30, 2025.
Earlier on Wednesday, Avalo Therapeutics, Inc. (NASDAQ:AVTX) appointed Rita Jain, M.D., to its Board of Directors. Dr Jain, who previously served as Executive Vice President and Chief Medical Officer at ChemoCentryx, joins the board at the company’s crucial time and plans to advance the Phase 2 LOTUS trial in HS, with results expected in mid-2026.
H.C. Wainwright analysts have upgraded Avalo Therapeutics, Inc. (NASDAQ:AVTX) to Buy from Neutral, while setting the 12-month price target to $15.00, implying an upside of over 200%. The leading candidate, AVTX-009, is what the analysts believe will lead the future of the company. The firm highlights that the mechanism represents an optimal strategy, stating that the competitor data reinforces the effectiveness of this risk-mitigated approach in treating the condition.
Avalo Therapeutics, Inc. (NASDAQ:AVTX), incorporated in 2001, operates as a clinical-stage biotechnology company that develops treatments for immune dysregulation in the United States. The core offering of this Maryland-based company is AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß.
2. Vistagen Therapeutics, Inc. (NASDAQ:VTGN)
Upside potential as of June 24, 2025: 521.53%
Analysts at Stifel reiterated their Buy rating on Vistagen Therapeutics, Inc. (NASDAQ:VTGN) with an unchanged price target of $12.00 post the company’s fiscal 2025 announcement. Earlier in the current quarter, the management announced that while the PAL-3 study is in the right direction to present results in the last quarter of 2025, there is a slight delay in the PAL-4 data readout to the first half of the upcoming year.
According to the management, the modest delay is associated with the use of enrollment projections from the PAL-2 study, together with the adoption of tight patient selection criteria so that the chances of success could be higher. The company noted that patient demand remains quite strong and is not attributed to this new update.
The research firm firmly believes that Vistagen Therapeutics, Inc. (NASDAQ:VTGN) has “a credible shot at success in either PAL-3/PAL-4,” which in turn would provide access to what the firm thinks is a large commercial opportunity in social anxiety disorder. Having said that, Stifel analysts maintain a “relatively low-risk, high-reward bet” on the company.
Vistagen Therapeutics, Inc. (NASDAQ:VTGN) is a California-based clinical-stage biopharmaceutical company that focuses on the development and commercialization of therapies for neuropsychiatric and neurological disorders. The core offerings of that company, which was founded in 1998, include Fasedienol(PH94B), Itruvone(PH10), PH80, and PH284.
1. Atossa Therapeutics, Inc. (NASDAQ:ATOS)
Upside potential as of June 24, 2025: 594.83%
Ascendiant Capital analysts slightly increased the price target for Atossa Therapeutics, Inc. (NASDAQ:ATOS) to $7.50, up from $7.25, with an unchanged Buy rating. This potential surge of 837% from current levels reinforces the company’s attractive valuation.
In making their judgment, the analysts noted that the updated price target is the perfect balance between the company’s high risks and its growth prospects. While analyzing the net present value of Atossa Therapeutics, Inc. (NASDAQ:ATOS), the firm pointed towards the company’s impressive liquidity position with a current ratio of 12.67. This is anything but ordinary.
Despite its associated risks, Atossa Therapeutics, Inc. (NASDAQ:ATOS) exhibits high upside opportunities. Just recently, the company highlighted its strategic moves in breast cancer at the Jefferies Conference. While utilizing Generative AI, Atossa Therapeutics will discover effective drug combinations, along with efforts to capitalize on the multi-billion-dollar market for estrogen receptor-positive breast cancer with Z endoxifen.
Atossa Therapeutics, Inc. (NASDAQ:ATOS) is a Washington-based clinical-stage biopharmaceutical company focused on developing medicines for women’s breast cancer and other oncological conditions. Founded in 2008, the company aims to transform breast cancer treatment through innovative and tailored solutions.
While we acknowledge the potential of ATOS to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ATOS and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email below.
